INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit
SAN DIEGO & CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- NantKwest ( Nasdaq:NK ), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company’s Chairman & CEO, Dr. Patrick Soon-Shiong , will be giving a keynote address at the Innate Killer
View HTML
Toggle Summary NantKwest to Participate at the Cowen & Company 39th Annual Health Care Conference
CULVER CITY, CA.- March 10, 2019 –  NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating and conducting one-on-one meetings at the Cowen 39th Annual Health Care Conference World Immunotherapy Congress
View HTML
Toggle Summary NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics
Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate for Multiple Myeloma, with an Option for up to Five Additional CAR Targeting Sequences SAN DIEGO --(BUSINESS WIRE)--Mar. 4, 2019-- NantKwest, Inc. (Nasdaq:NK) , a leading clinical-stage Natural Killer (NK)
View HTML
Toggle Summary NantKwest to Participate at World Immunotherapy Congress
CULVER CITY, CA – March 1, 2019 - NantKwest (Nasdaq:NK), a member of the NantWorks ecosystem of companies,  a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be making two presentations at the World Immunotherapy Congress in San Diego on
View HTML
Toggle Summary NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy
Study Tests Elimination Of Chemotherapy And Expands Upon Previous Combination Study Of NK Cell Therapy With N-803 Showing Promising Clinically Meaningful Responses In Merkel Cell Carcinoma Patients CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 9, 2019-- NantKwest Inc .
View HTML
Toggle Summary NantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 5, 2019-- NantKwest (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary Nantcell announces new Celgene Investment
Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7th Second Round Crossover Funding Brings Celgene’s Investment to $105M in NantCell Valued at $4 Billion Currently Enrolling Patients in Advanced Stage Trials in 15 Indications for
View HTML
Toggle Summary NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology
Novel Trispecific CD19.t-haNK TM Natural Killer Cell Therapy Engineered for Enhanced Tumor Homing for B Cell Lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 3, 2018-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the
View HTML
Toggle Summary NantKwest to Participate at Upcoming Investment Conferences
NantKwest to Participate at Upcoming Investment Conferences CULVER CITY, CALIFORNIA-(BUSINESS WIRE), November 12, 2018 NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating at a number of investment
View HTML
Toggle Summary NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine Immunotherapy
Combination in 30 Patients with Advanced Metastatic Cancer Refractory to Multiple Previous Therapies Zero Incidence of Cytokine Release Syndrome in Any of the 300 Doses in 30 Patients All Patients Received NK Cell Infusion and Novel Cancer Memory Vaccine Combination as Outpatients with No
View HTML